Advertisement
U.S. Markets closed
S&P Futures
5,885.00 -7.50 (-0.13%) Dow Futures
43,030.00 -139.00 (-0.32%) Nasdaq Futures
20,505.00 -37.00 (-0.18%) Russell 2000 Futures
2,244.10 -2.10 (-0.09%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,759.90 +0.10 (+0.00%)
Pasithea Therapeutics Corp. (KTTA)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
| Previous Close | 4.3900 |
| Open | 4.3300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.2300 - 4.3900 |
| 52 Week Range | 3.6100 - 17.4000 |
| Volume | |
| Avg. Volume | 934,018 |
| Market Cap | 4.42M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.7900 |
| Earnings Date | Aug 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,219,513 shares of its common stock (or pre-funded warrants in lieu thereof), accompanyin
- MT Newswires
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care Stocks Mixed Late Afternoon
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.